PAR-26-150
Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Summary
Early-Onset Cancer Etiology and Prevention Research
The National Cancer Institute seeks research that explains why non-hereditary cancers are rising in young adults (ages 18–49) and identifies actionable prevention strategies. This NOFO targets three interconnected questions: which modifiable exposures—and how do they differ across demographic groups—are fueling the increase in early-onset cancers (EOCs); what biological mechanisms and host responses underlie this trend; and how can clinicians better identify individuals at elevated risk. Research spanning cancer biology, epidemiology, and prevention science is welcome, with emphasis on sporadic (non-hereditary) disease and the integration of mechanistic insights with population-level evidence to inform cancer control.
At a glance:
- Who can apply: U.S. institutions and eligible foreign organizations; no restrictions stated beyond standard NIH requirements
- Funding & project length: Up to $250,000 (exploratory/developmental, 2 years) or $500,000 (research project, 4–5 years); exact amounts not stated in FOA
- Award mechanism: R21 (exploratory/developmental) or R01 (research project)
- Key dates: Not stated
- Best fit for: Cancer epidemiologists, molecular biologists, and prevention researchers investigating modifiable risk factors, biological mechanisms, and susceptibility in young adults with non-hereditary cancers
Insights (5)
Early-onset cancer focus demands novel mechanistic or epidemiologic approaches
This NOFO explicitly targets the 'unexplained rise' in cancers among ages 18–49, signaling NCI's interest in non-traditional risk factors and mechanisms distinct from hereditary or late-life cancer biology. Competitive applications will likely feature preliminary data on modifiable exposures (lifestyle, environmental, reproductive, metabolic) or host-response mechanisms (immune, microbiome, hormonal) that differentiate EOC from older-onset disease. Generic cancer biology or standard epidemiology without an EOC-specific angle will struggle.
Dual-mechanism structure (R21/R01) creates two distinct competitive pools
By consolidating exploratory (R21, up to 2 years) and traditional research (R01, 4–5 years) into one NOFO, NCI is likely expecting a mix of high-risk/high-reward pilot studies and mature, well-powered investigations. R21 applicants can test novel hypotheses with less preliminary data; R01 applicants face higher expectations for feasibility and impact. The mechanism choice signals your career stage and project maturity—misalignment (e.g., underpowered R01 or overly preliminary R21) will disadvantage you.
Demographic variation in EOC etiology is an explicit priority
The NOFO emphasizes 'how do these factors vary by patient demographics,' suggesting NCI values studies that disaggregate risk by race, ethnicity, socioeconomic status, or other social determinants. Applications that treat EOC as a monolithic entity without addressing disparities or intersectionality will be less competitive than those integrating demographic stratification into study design or analysis plans.
Age range 18–49 is narrow; study population definition is critical
The strict age window (18–49 years) for case definition may exclude valuable comparative data from slightly older cohorts or require careful age-stratification in existing datasets. If your preliminary data or cohort spans broader ages, you must clearly justify how you will isolate the 18–49 population and ensure sufficient statistical power. Retrospective studies relying on registry data should confirm age-at-diagnosis coding accuracy.
Multi-disciplinary teams strengthen mechanistic and prevention translation
The three research aims (modifiable exposures, biological mechanisms, risk identification) span epidemiology, molecular biology, and clinical implementation. While not explicitly required, applications integrating epidemiologists, basic scientists, and clinicians will be better positioned to address the full scope and demonstrate translational potential. Single-PI studies focused narrowly on one aim may appear incomplete.
Key Facts
Deadline
—
Posted
Tue, March 10, 2026
Max Duration
5 years
Keywords
Research Areas
Gotchas (1)
Applicants must choose between two distinct project period options (2 years vs. 4-5 years) with no middle ground, and the choice may affect mechanism classification and review criteria, but the NOFO d
72%
Source Text
“Applicants have the option of submitting either an exploratory/developmental research project with a project period of up to 2 years or a research project with a project period of 4 to 5 years.”